Georgia launches a pilot program for injectable PrEP

Georgia plans to introduce a long-acting injectable medication, lenacapavir, for the prevention of HIV infection. Initially, the initiative will be implemented as a pilot program, with a limited number of beneficiaries participating.

Lenacapavir is used for HIV/AIDS prevention and requires only two injections per year, administered once every six months. In June 2025, the U.S. Food and Drug Administration (FDA) approved the medication for HIV pre-exposure prophylaxis (PrEP). Due to its high efficacy, the approval was described as a significant advance by the international medical community.

HIV pre-exposure prophylaxis (PrEP) is a modern and reliable method of HIV prevention. Before the introduction of this new medication, PrEP was available worldwide in several forms: vaginal rings, an injectable form administered once every two months, and pills taken either daily or on an as-needed basis.

Georgia was the first country in the region to introduce a pilot PrEP program in 2017. Currently, PrEP in the country is administered only in tablet form. Equality Movement, the organization providing PrEP services, continues to actively promote HIV prevention. At present, more than 2,700 beneficiaries are enrolled in the PrEP program.

PrEP services are completely free and anonymous.